Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide and Tirzepatide With or Without Exercise in Obesity
NCT07319975Not yet recruiting
- Sponsor
- Istanbul Galata University
- Start
- Dec 2025
- Primary completion
- Oct 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised trial of semaglutide and tirzepatide in obesity (4 arms), sponsored by Istanbul Galata University. Primary endpoint: Body fat-muscle ratios at 3 months. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07319975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07319975.